Concentra Group Holdings Parent, Inc. (CON)
NYSE: CON · Real-Time Price · USD
42.55
-0.44 (-1.02%)
At close: Nov 13, 2026, 4:00 PM EST
42.52
-0.03 (-0.07%)
Pre-market: Nov 16, 2026, 8:23 AM EST

Concentra Group Holdings Parent Earnings Call Transcripts

Fiscal Year 2026

Fiscal Year 2025

  • Revenue and Adjusted EBITDA exceeded guidance in 2025, driven by strong organic growth, successful acquisitions, and cost efficiencies. 2026 guidance projects continued growth, margin stability, and robust capital deployment, with a focus on de novos and small M&A.

  • Q3 2025 saw 17% revenue growth and strong adjusted EBITDA, driven by organic and acquisition-fueled expansion. Guidance for 2025 was raised, with continued focus on deleveraging, technology investment, and disciplined M&A. No major headwinds are anticipated for 2026.

  • Q2 2025 saw strong revenue and visit growth, successful integration of major acquisitions, and raised full-year guidance. Margins were slightly lower due to one-time costs, but cash flow and deleveraging remain on track. No major reimbursement or labor risks identified.

  • The group maintains a leading position in occupational health, with diversified revenue from workers' comp and employer services. Growth is driven by steady visit volumes, inflation-linked pricing, and expansion through acquisitions and new service offerings. Leverage is targeted to decline as integration and cash flow improve.

  • Q1 2025 saw strong revenue and adjusted EBITDA growth, driven by visit and rate increases and major acquisitions. Guidance for 2025 was raised, reflecting robust performance and recent M&A, with a focus on integration and deleveraging.

  • Guidance

    Preliminary 2024 results exceeded expectations, with strong revenue and EBITDA growth. The Nova Medical Centers acquisition will expand the footprint, especially in Texas, and is expected to be immediately accretive. 2025 guidance projects double-digit revenue and EBITDA growth.

Fiscal Year 2024